Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

Metformin is considered to be one of the most effective therapeutics for the treatment of type 2 diabetes (T2D) since it specifically reduces hepatic gluconeogenesis without increasing insulin secretion, inducing weight gain, or posing a risk of hypoglycemia1,2. For over half a century, this agent h...

Full description

Bibliographic Details
Main Authors: Madiraju, Anila K., Erion, Derek M., Rahimi, Yasmeen, Zhang, Xian-Man, Braddock, Demetrios, Albright, Ronald A., Prigaro, Brett J., Wood, John L., Bhanot, Sanjay, MacDonald, Michael J., Jurczak, Michael, Camporez, Joao-Paulo, Lee, Hui-Young, Cline, Gary W., Samuel, Varman T., Kibbey, Richard G., Shulman, Gerald I.
Format: Online
Language:English
Published: 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074244/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074244/

Similar Items